No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

Casgevy (exagamglogene autotemcel or exa-cel) became the first drug based on the CRISPR/Cas9 gene-editing technology ... application of the technology, meaning that bone marrow stem cells are ...

Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

CRISPR Therapeutics (NASDAQ: CRSP) stock climbed 7% after receiving an upgrade from Evercore ISI, shifting from an In Line rating to Outperform. The biotechnology company, known for its CRISPR/Cas9 ...